299 related articles for article (PubMed ID: 11583721)
1. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus.
Ichimaru N; Takahara S; Kokado Y; Wang JD; Hatori M; Kameoka H; Inoue T; Okuyama A
Atherosclerosis; 2001 Oct; 158(2):417-23. PubMed ID: 11583721
[TBL] [Abstract][Full Text] [Related]
2. Long term efficacy of simvastatin in renal transplant recipients treated with cyclosporine or tacrolimus.
Imamura R; Ichimaru N; Moriyama T; Shi Y; Namba Y; Nonomura N; Matsumiya K; Toki K; Takahara S; Okuyama A
Clin Transplant; 2005 Oct; 19(5):616-21. PubMed ID: 16146552
[TBL] [Abstract][Full Text] [Related]
3. Effect of simvastatin on the lipid profile of hemodialysis patients.
Nishikawa O; Mune M; Miyano M; Nishide T; Nishide I; Maeda A; Kimura K; Takahashi T; Kishino M; Tone Y; Otani H; Ogawa A; Maeda T; Yukawa S
Kidney Int Suppl; 1999 Jul; 71():S219-21. PubMed ID: 10412781
[TBL] [Abstract][Full Text] [Related]
4. Correlation between lipid abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal function.
Perrea DN; Moulakakis KG; Poulakou MV; Vlachos IS; Nikiteas N; Kostakis A
Int Urol Nephrol; 2008; 40(2):521-7. PubMed ID: 17978855
[TBL] [Abstract][Full Text] [Related]
5. Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients.
Capone D; Stanziale P; Gentile A; Imperatore P; Pellegrino T; Basile V
Am J Nephrol; 1999; 19(3):411-5. PubMed ID: 10393380
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients.
Penson MG; Fricker FJ; Thompson JR; Harker K; Williams BJ; Kahler DA; Schowengerdt KO
J Heart Lung Transplant; 2001 Jun; 20(6):611-8. PubMed ID: 11404165
[TBL] [Abstract][Full Text] [Related]
7. Effects of cyclosporine-tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2/3, lipoprotein a1/b, and other lipid parameters.
Seymen P; Yildiz M; Türkmen MF; Titiz MI; Seymen HO
Transplant Proc; 2009 Dec; 41(10):4181-3. PubMed ID: 20005364
[TBL] [Abstract][Full Text] [Related]
8. The effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study.
Türk S; Yildiz A; Tükek T; Akkaya V; Aras U; Türkmen A; Uras AR; Sever MS
Int Urol Nephrol; 2001; 32(4):713-6. PubMed ID: 11989571
[TBL] [Abstract][Full Text] [Related]
9. New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine?
Deleuze S; Garrigue V; Delmas S; Chong G; Swarcz I; Cristol JP; Mourad G
Transplant Proc; 2006 Sep; 38(7):2311-3. PubMed ID: 16980075
[TBL] [Abstract][Full Text] [Related]
10. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study.
McCune TR; Thacker LR II; Peters TG; Mulloy L; Rohr MS; Adams PA; Yium J; Light JA; Pruett T; Gaber AO; Selman SH; Jonsson J; Hayes JM; Wright FH; Armata T; Blanton J; Burdick JF
Transplantation; 1998 Jan; 65(1):87-92. PubMed ID: 9448150
[TBL] [Abstract][Full Text] [Related]
11. Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia.
Li PK; Mak TW; Chan TH; Wang A; Lam CW; Lai KN
Transplantation; 1995 Oct; 60(7):652-6. PubMed ID: 7570971
[TBL] [Abstract][Full Text] [Related]
12. Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia.
Saku K; Sasaki J; Arakawa K
Clin Ther; 1989; 11(2):247-57. PubMed ID: 2736571
[TBL] [Abstract][Full Text] [Related]
13. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation.
Wissing KM; Unger P; Ghisdal L; Broeders N; Berkenboom G; Carpentier Y; Abramowicz D
Transplantation; 2006 Sep; 82(6):771-8. PubMed ID: 17006324
[TBL] [Abstract][Full Text] [Related]
14. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion.
White M; Haddad H; Leblanc MH; Giannetti N; Pflugfelder P; Davies R; Isaac D; Burton J; Chan M; Azevedo E; Howlett J; Ignaszewski A; Busque S; Cantarovich M; Ferguson R; Genest J; Ross H
J Heart Lung Transplant; 2005 Jul; 24(7):798-809. PubMed ID: 15982605
[TBL] [Abstract][Full Text] [Related]
15. A double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients.
Lepre F; Rigby R; Hawley C; Saltissi D; Brown A; Walsh Z
Clin Transplant; 1999 Dec; 13(6):520-5. PubMed ID: 10617243
[TBL] [Abstract][Full Text] [Related]
16. Lipid profiles in pediatric thoracic transplant recipients are determined by their immunosuppressive regimens.
Law YM; Yim R; Agatisa P; Boyle GJ; Miller SA; Lawrence K; Webber SA
J Heart Lung Transplant; 2006 Mar; 25(3):276-82. PubMed ID: 16507419
[TBL] [Abstract][Full Text] [Related]
17. Impact of fluvastatin on hyperlipidemia after renal transplantation.
Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients.
Manzarbeitia C; Reich DJ; Rothstein KD; Braitman LE; Levin S; Munoz SJ
Liver Transpl; 2001 Feb; 7(2):93-9. PubMed ID: 11172391
[TBL] [Abstract][Full Text] [Related]
19. Ezetimibe is effective in the treatment of persistent hyperlipidemia of renal allograft recipients.
Savvidaki E; Koukoulaki M; Benou A; Roumeliotou M; Fourtounas C; Kalliakmani P; Papachristou E; Vlachojannis JG; Goumenos D
Clin Nephrol; 2011 Feb; 75(2):107-12. PubMed ID: 21255539
[TBL] [Abstract][Full Text] [Related]
20. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus.
Taylor DO; Barr ML; Radovancevic B; Renlund DG; Mentzer RM; Smart FW; Tolman DE; Frazier OH; Young JB; VanVeldhuisen P
J Heart Lung Transplant; 1999 Apr; 18(4):336-45. PubMed ID: 10226898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
